[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632754":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":54,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":26,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Western Galilee Hospital-Nahariya","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"papaverine arm","ACTIVE_COMPARATOR","IV-papaverine 80 mg in 100 ml 0.9% saline, once, 12 hours after rupture of membranes",[13],"Drug: Papaverine arm",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","PLACEBO_COMPARATOR","I.V 100 ml 0.9% saline, 12 hours after rupture of membranes",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Papaverine arm","given 12 houres after rupture of membranes",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"OTHER","Placebo","I.V seline",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Maya Frank Wolf, professor","CONTACT","• 972:50-7887800","mayaw@gmc.gov.il",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Galilee Medical Center","RECRUITING","Nahariya","Israel","IL",{"type":46,"coordinates":47},"Point",[48,49],35.09814,33.00892,{"lat":49,"lon":48},[52],{"name":34,"role":35,"phone":53,"phoneExt":26,"email":37},"+972507887800",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dr. Maya Wolf","Head of Fetal Maternal Unit","100632754","phase-4-iv-papavrine-for-labor-induction-in-term-prom-100632754",false,"NCT07517796","I.V Papavrine for Labor Induction in Term PROM","I.V Papavrine for Labor Induction in Term PROM: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* • Singleton pregnancy\n\n  * Term gestation (37-42 weeks)\n  * Term PROM prior to active labor\n  * Duration of PROM \\\u003C12 hours at enrollment\n  * Bishop score \\\u003C8\n  * Cephalic presentation\n  * Viable fetus with reassuring fetal heart rate\n\nExclusion Criteria:\n\n* • Multiple gestation\n\n  * Previous cesarean delivery\n  * Major fetal anomalies\n  * Contraindication to vaginal delivery\n  * Meconium-stained amniotic fluid\n  * Suspected chorioamnionitis",true,"FEMALE","18 Years","45 Years",{"count":70,"type":71},110,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo",[77],"Premature Rupture of Membranes",[79,80,81],"premature rupture of membranes","papaverine","bishop score","2026-04-03",{"date":84,"type":85},"2026-04-08","ACTUAL",{"date":87,"type":85},"2025-10-22",{"date":89,"type":71},"2027-10-22",{"name":5,"class":6},1]